Effects of Trimetazidine on Heart Rate Variability and Left Ventricular Systolic Performance in Patients with Coronary Artery Disease After Percutaneous Transluminal Angioplasty
| Autor: | Gulmira Z. Kudaiberdieva, Ahmet Birand, Ayhan Usal, Ferit Akgül, Talantbek Batyraliev |
|---|---|
| Přispěvatelé: | Çukurova Üniversitesi |
| Rok vydání: | 1997 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Vasodilator Agents medicine.medical_treatment Trimetazidine Ischemia Coronary Disease Myocardial Reperfusion Injury 030204 cardiovascular system & hematology Doppler echocardiography Ventricular Function Left Coronary artery disease Angina 03 medical and health sciences 0302 clinical medicine Heart Rate Internal medicine Angioplasty Heart rate Humans Medicine Heart rate variability cardiovascular diseases 030212 general & internal medicine Angioplasty Balloon Coronary medicine.diagnostic_test business.industry Signal Processing Computer-Assisted Middle Aged medicine.disease Myocardial Contraction Echocardiography Doppler Echocardiography Anesthesia Cardiology Female Cardiology and Cardiovascular Medicine business Follow-Up Studies medicine.drug |
| Zdroj: | Angiology. 48:413-422 |
| ISSN: | 1940-1574 0003-3197 |
| DOI: | 10.1177/000331979704800505 |
| Popis: | Fifty-one patients (mean age 51.6 ± 7.1 years) with angiographically proven coronary artery disease (CAD) entered the study. In 26 patients (Group I), trimetazidine treatment started twenty-four hours after percutaneous transluminal coronary angioplasty (PTCA). Another 25 patients (Group II) without trimetazidine treatment were kept as controls. The groups were comparable by age, gender, risk factors of CAD, coronary anatomy, left ventricular performance, and heart rate variability indices at baseline state. Power spectral analysis of heart rate variability and two-dimensional and Doppler echocardiographic examinations were performed before PTCA, and twenty-four hours, ten days, thirty days, and three months after PTCA. A statistically significant improvement of left ventricular systolic performance (P In conclusion, trimetazidine modulates the autonomic control of heart rate, ie, reduces sympathetic overactivity and augments vagal influences, improves left ventricular contractility, and diminishes the clinical manifestations of ischemia in patients with CAD after PTCA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|